Real-world prognostic factors for first-line EGFR-TKI efficacy in advanced NSCLC patients harboring <i>EGFR</i> 21 L858R mutation.

Although the multivariate analysis in our study did not reach statistical significance, which could be due to the limited sample size, this emerging evidence underscores the critical role of co-occurring genomic alterations in shaping tumor heterogeneity and therapeutic responses.

also in 111,027 other papers